Natco Pharma gets CDSCO nod for use of Baricitinib in Covid patients

Natco Pharma has secured emergency use approval for Baricitinib from India‘s Central Drugs Standard Control Organization (CDSCO) for the treatment of Covid-19.

The Indian pharma company has been given the nod for Lilly’s oral JAK1/JAK2 inhibitor in 1mg, 2mg and 4mg strengths in combination with Remdesivir.

Natco Pharma said that it will be seeking a compulsory license based on emergency use and on the basis of grim public health emergency across India because of the second wave of the coronavirus pandemic.

Natco Pharma gets CDSCO nod for use of Baricitinib in Covid patients. Image courtesy of Daniel Roberts from Pixabay.

The Hyderabad-based pharma company is ready to release the product this week, in order to make it available to patients suffering from Covid-19 across India.